Please assess the completion status of the following clinical trial:

Trial Title: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Obtained written informed consent~2. Patients must have histologically confirmed peripheral T-cell lymphoma according to the 2016 revision of the World Health Organization classiﬁcation of lymphoid neoplasms. Tumor samples are required for central pathology review to confirm the diagnosis.~3. Patients must have measurable disease according to the Lugano criteria.~4. Patients should be transplant-ineligible upon their entry into this study, and must have relapsed after or been refractory/intolerant to ≥ 1 (but not \> 3) prior systemic therapy(ies) for PTCL.~5. Adequate bone marrow reserve and organ system functions.~Exclusion Criteria:~1. Any unsolved toxicity \> Common Terminology Criteria for Adverse Events (CTCAE) grade 1 from previous anti-cancer therapy (except alopecia).~2. Active infections, active or latent tuberculosis.~3. Patients with severely decreased lung function.~4. History of heart failure or QT interval prolongation.~5. Central nervous system (CNS) or leptomeningeal lymphoma.~6. History of treatment with Janus kinase (JAK) or signal transducer and activator of transcription 3 (STAT3) inhibitor.~7. Patient has undergone an allogeneic stem cell transplant. Patient had autologous stem cell transplant within 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AZD4205 Group A (Type: EXPERIMENTAL): Group A: Open label AZD4205 at dose A, once daily (Phase 1)
- AZD4205 Group B (Type: EXPERIMENTAL): Group B: Open label AZD4205 at dose B, once daily (Phase 1)
- AZD4205 Group C (Type: EXPERIMENTAL): Group C: Open label AZD4205 at a selected dose, once daily (Phase 1)
- AZD4205 Group D (Type: EXPERIMENTAL): Group D: Open label AZD4205 at the RP2D, once daily (Phase 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).